Immunic AG | Finanzwire

Basculer en Français

8295	Companies
114833	Keywords
55274	Articles
62430	Press releases

Home
Companies
Immunic AG

BRIEF

published on 11/13/2024 at 12:35, 7 days 22 hours ago

Immunic Publishes Phase 1/1b Trial Data of IMU-856 in The Lancet

Clinical Trial Immunic Gastroenterology IMU-856 Celiac Disease
PRESS RELEASE

published on 11/13/2024 at 12:30, 7 days 22 hours ago

Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology
Immunic announces publication of phase 1/1b clinical trial data of IMU-856 in The Lancet Gastroenterology & Hepatology. Positive results in celiac disease patients. Potential new approach for gastrointestinal diseases

Gastrointestinal Diseases Clinical Trial Immunic IMU-856 Celiac Disease
BRIEF

published on 11/07/2024 at 12:35, 13 days 22 hours ago

Immunic, Inc. Reports Q3 2024 Financial Results

Financial Results Vidofludimus Calcium Phase 3 ENSURE Trials Multiple Sclerosis Research Clinical Trial Updates
PRESS RELEASE

published on 11/07/2024 at 12:30, 13 days 22 hours ago

Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Immunic, Inc. reports Q3 2024 financial results, positive Phase 3 ENSURE Program interim analysis. Twin Phase 3 ENSURE trials and Phase 2 CALLIPER trial on track. Webcast held on Nov 7. IMUX stock update

Financial Results Immunic Inc. Q3 2024 Phase 3 ENSURE Program IMUX Stock
BRIEF

published on 10/31/2024 at 11:35, 20 days 23 hours ago

Immunic, Inc. to Release Q3 2024 Financial Results and Corporate Update

Financial Results Biotechnology Clinical Trials Webcast Immunic
PRESS RELEASE

published on 10/31/2024 at 11:30, 20 days 23 hours ago

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update
Immunic, Inc. (Nasdaq: IMUX) to release Q3 financial results and corporate update on Nov 7, 2024. Webcast at 8:00 am ET. Company developing therapies for inflammatory and autoimmune diseases. Visit www.imux.com for more info

Financial Results Biotechnology Corporate Update Immunic Inc. Clinical Pipeline
BRIEF

published on 10/29/2024 at 11:35, 22 days 23 hours ago

Immunic to Participate in Key Conferences Throughout November

Investors Biotechnology Clinical Trials Conférences Immunic
PRESS RELEASE

published on 10/29/2024 at 11:30, 22 days 23 hours ago

Immunic to Participate in Industry, Scientific and Investor Conferences in November
Immunic to participate in industry, scientific, and investor conferences in November 2024, presenting data on IMU-856 for celiac disease. Details on events and presentations available on company website

Clinical Trials Conférences Investor Immunic Scientific
BRIEF

published on 10/22/2024 at 12:35, 29 days 22 hours ago

Immunic Reports Positive Interim Results for Phase 3 ENSURE Program

Biotechnology Vidofludimus Calcium Phase 3 Trials Relapsing Multiple Sclerosis Interim Analysis
PRESS RELEASE

published on 10/22/2024 at 12:30, 29 days 22 hours ago

Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis
Immunic announces positive outcome of interim analysis of Phase 3 ENSURE Program for vidofludimus calcium in RMS. Trials recommended to continue unchanged till 2026

Multiple Sclerosis Immunic Vidofludimus Calcium Phase 3 ENSURE Program

1 2 ... 4

Accesswire

Published on 11/21/2024 at 10:03, 49 minutes ago

Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 52 minutes ago

BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 09:00, 1 hour 52 minutes ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 10 hours 17 minutes ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 10 hours 27 minutes ago

Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 10:30, 22 minutes ago

MS Industrie AG publishes unaudited key figures for the first 3 quarters 2024
Published on 11/21/2024 at 10:04, 47 minutes ago

Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:02, 49 minutes ago

Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:00, 52 minutes ago

Nabaltec AG continues solid earnings performance in third quarter of 2024
Published on 11/21/2024 at 10:00, 52 minutes ago

Deutsche Beteiligungs AG: Successful final closing of DBAG ECF IV

Les Echos

Published on 11/21/2024 at 06:58, 3 hours 54 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 15 hours 32 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 17 hours 7 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 17 hours 7 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 3 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE